Edgewise Therapeutics to Present Phase 2 Data on EDG-7500 at ESC Congress

Dr. Anjali Tiku Owens, an associate professor at the Perelman School of Medicine, is scheduled to present the findings on August 31, 2026. The data stems from the CIRRUS-HCM study, which examined the safety and efficacy of the oral treatment in both obstructive and nonobstructive forms of the condition. EDG-7500 functions by slowing early cardiac contraction and improving relaxation, aiming to address the diastolic dysfunction that characterizes the disease.

Hypertrophic cardiomyopathy affects roughly one in 500 individuals, often resulting in debilitating symptoms like breathlessness, chest pain, and fainting due to the thickening of the left ventricular wall. Because the disease can lead to severe complications such as heart failure and sudden cardiac death, researchers are closely watching how this selective modulator performs in a 12-week clinical setting. Following the live session in Hall A3, Edgewise plans to publish the presentation materials on its corporate website.